Especially when you consider most pharma companies seem to make around 15-30% profit after all costs/R&D... not many industries manage those kind of numbers.
You are looking at a biased data set is why. You are looking at the biggest drug manufacturers in the world which most likely own the most lucrative drugs. If you want a more unbiased sample then you need to look at the entire industry. For small drug companies most of the time their drugs do not get FDA approval or doesn't pass some regulatory approval and the whole company folds. For the bigger drug companies, the trend isn't to increase R&D spending but rather to simply buy up smaller companies that have patented drugs. This makes sense though because of eroom's law which states that even with advanced technology...creating new drugs or discovering new treatments is getting harder (more expensive) which means that the rate of return for drug R&D is declining.
There's plenty of industries that do. Tech makes much more. In fact, pharma on average spends a greater proportion of revenue on R&D than just about any other industry.
